Aims:
To examine the injecting and sexual risk behaviours of gay men in London who use anabolic steroids or other fitness-enhancing substances (referred to as AS).
Design:
Cross-sectional survey using self-administered questionnaire.
Setting:
Five gyms in central London.
Participants:
1004 gay men using the gyms during September-October 1997.
Measurements:
Proportion of men who report (i) injecting AS, (ii) sharing needles and (iii) HIV status-unknown unprotected and intercourse (UAI).
Findings:
Of 1004 men, 136 (13.5%) were current users of AS (range across the five gyms, 2.7-21.2%, p < 0.001), and 81 (8.1%) injected AS (range 0.4-17.5%, p < 0.001). None said they shared a needle with other users and more than 90% said they always used disposable units from sealed packets. Among current AS users, 20.9% (28/136) reported status-unknown UAI compared with 12.9% (107/827) of never-users (p = 0.02), a differential which remained significant after adjusting for confounding factors (adjusted odds ratio = 1.75, 95% CI 1.05, 2.91, p = 0.03).
Conclusions:
While nearly one in 10 gay men in this study injected anabolic steroids or other fitness-enhancing substances, none reported sharing needles. Steroid users were, however, more likely to report status-unknown UAI than other men, a differential that remained after adjusting for confounding factors. Since any change in injecting practice could dramatically increase the risk of HIV transmission in this population, behavioural surveillance to monitor risk behaviours among gay men using anabolic steroids is recommended, as are targeted HIV prevention programmes.
Citing Articles
Harm reduction techniques among cisgender gay, bisexual, and queer men using anabolic androgenic steroids: a qualitative study.
Kutscher E, Arshed A, Greene R, Kladney M
Harm Reduct J. 2024; 21(1):196.
PMID: 39523302
PMC: 11552109.
DOI: 10.1186/s12954-024-01121-8.
Exploring Anabolic Androgenic Steroid Use Among Cisgender Gay, Bisexual, and Queer Men.
Kutscher E, Arshed A, Greene R, Kladney M
JAMA Netw Open. 2024; 7(5):e2411088.
PMID: 38743422
PMC: 11094559.
DOI: 10.1001/jamanetworkopen.2024.11088.
Prevalence of anabolic steroid users seeking support from physicians: a systematic review and meta-analysis.
Amaral J, Kimergard A, Deluca P
BMJ Open. 2022; 12(7):e056445.
PMID: 35788077
PMC: 9255415.
DOI: 10.1136/bmjopen-2021-056445.
Appearance and performance-enhancing drugs and supplements (APEDS): Lifetime use and associations with eating disorder and muscle dysmorphia symptoms among cisgender sexual minority people.
Nagata J, McGuire F, Lavender J, Brown T, Murray S, Compte E
Eat Behav. 2022; 44:101595.
PMID: 35066385
PMC: 9359347.
DOI: 10.1016/j.eatbeh.2022.101595.
Injection of Anabolic Steroids in Men Who Had Sex with Men in Madrid and Barcelona: Prevalence Correlates and Role as a Risk Factor for Transmitted Infections.
Guerras J, Hoyos J, de La Fuente L, Roman F, Ayerdi O, Garcia-Perez J
Int J Environ Res Public Health. 2021; 18(16).
PMID: 34444038
PMC: 8391652.
DOI: 10.3390/ijerph18168289.
Anabolic androgenic steroid abuse in the United Kingdom: An update.
Mullen C, Whalley B, Schifano F, Baker J
Br J Pharmacol. 2020; 177(10):2180-2198.
PMID: 31989581
PMC: 7174889.
DOI: 10.1111/bph.14995.
Treatments for people who use anabolic androgenic steroids: a scoping review.
Bates G, Van Hout M, Teck J, McVeigh J
Harm Reduct J. 2020; 16(1):75.
PMID: 31888665
PMC: 6937954.
DOI: 10.1186/s12954-019-0343-1.
Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject Image and Performance Enhancing Drugs in England and Wales: Results From Cross-Sectional Prevalence Surveys, 1992-2013.
Hope V, Harris R, McVeigh J, Cullen K, Smith J, Parry J
J Acquir Immune Defic Syndr. 2015; 71(3):331-7.
PMID: 26361173
PMC: 4770362.
DOI: 10.1097/QAI.0000000000000835.
Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.
Pope Jr H, Wood R, Rogol A, Nyberg F, Bowers L, Bhasin S
Endocr Rev. 2014; 35(3):341-75.
PMID: 24423981
PMC: 4026349.
DOI: 10.1210/er.2013-1058.
Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study.
Hope V, McVeigh J, Marongiu A, Evans-Brown M, Smith J, Kimergard A
BMJ Open. 2013; 3(9):e003207.
PMID: 24030866
PMC: 3773656.
DOI: 10.1136/bmjopen-2013-003207.
A league of their own: demographics, motivations and patterns of use of 1,955 male adult non-medical anabolic steroid users in the United States.
Cohen J, Collins R, Darkes J, Gwartney D
J Int Soc Sports Nutr. 2007; 4:12.
PMID: 17931410
PMC: 2131752.
DOI: 10.1186/1550-2783-4-12.
HIV in East London: ethnicity, gender and risk. Design and methods.
Elford J, Anderson J, Bukutu C, Ibrahim F
BMC Public Health. 2006; 6:150.
PMID: 16764715
PMC: 1524742.
DOI: 10.1186/1471-2458-6-150.
HIV risk profile of male street youth involved in survival sex.
Haley N, Roy E, Leclerc P, Boudreau J, Boivin J
Sex Transm Infect. 2004; 80(6):526-30.
PMID: 15572629
PMC: 1744937.
DOI: 10.1136/sti.2004.010728.
Trends in sexual behaviour among London homosexual men 1998-2003: implications for HIV prevention and sexual health promotion.
Elford J, Bolding G, Davis M, Sherr L, Hart G
Sex Transm Infect. 2004; 80(6):451-4.
PMID: 15572612
PMC: 1744925.
DOI: 10.1136/sti.2004.010785.